Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
HLA-DRB1*1501 tagging rs3135388 polymorphism is not associated with neuromyelitis optica.
GlaxoSmithKline Protocol Summaries: Firategrast
FGF2 and FGFR1 signaling regulate functional recovery following cuprizone demyelination.
National MS Society: Sylvia Lawry Physician Fellowships
Management of worsening multiple sclerosis with mitoxantrone: a review.
Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.
Clinically isolated syndrome - Rethinking the diagnosis.
Episode 1 with Dr. Timothy Vollmer on maintaining brain health
28th Congress of European Committee for Treatment and Research in Multiple Sclerosis Congress
IL-2Rβγ-signaling contributes to regulatory T cell maintenance and stability in daclizumab HYP-treated RRMS patients
Teriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis.
Experimental models of spontaneous autoimmune disease in the central nervous system.
Setting a research agenda for progressive multiple sclerosis: The International Collaborative on Progressive MS.
Cost-Effectiveness of Treatments for Relapsing Remitting Multiple Sclerosis: A French Societal Perspective.
Sex differences in autoimmune disease.
Sex differences in autoimmune diseases.
Cerebrospinal fluid data compilation and knowledge-based interpretation of bacterial, viral, parasitic, oncological, chronic inflammatory and demyelinating diseases. Diagnostic patterns not to be missed in neurology and psychiatry.
Quantifying the early stages of remyelination following cuprizone-induced demyelination.
Macrophage depletion impairs oligodendrocyte remyelination following lysolecithin-induced demyelination.
Webinar: Solutions for Genome Editing: TALEN, CRISPR, & Safe Harbor Integration
Breast-feeding, postpartum and prepregnancy disease activity in multiple sclerosis.
Episode 23 with Professor Aksel Siva discussing radiologically isolated syndrome (RIS)
Cognitive Test Analysis May Determine Reliable MS Change Over Time
Teva Receives Positive Outcome in Europe for Three-Times-a-Week COPAXONE® (Glatiramer Acetate) 40 mg/ml for the Treatment of Relapsing Forms of Multiple Sclerosis (RMS)
Episode 39 with Dr. Joseph Berger on diagnostic dilemmas in MS
Pages
« first
‹ previous
…
51
52
53
54
55
56
57
58
59
…
next ›
last »